Skip to main content

Childhood Cancer and Blood Disorders

The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.

Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.

Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours

Blog

News

The European PERIFORMANCE project promotes the donation of paediatric control samples, with the participation of families and healthcare professionals in biomedical research.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

Vall d'Hebron is one of the centers that coordinate this network, which so far has enabled the detection of high-risk genetic alterations and the provision of personalized treatments that have already achieved remission in cases with very few therapeutic alternatives.